ZinserLab will focus on accelerating the development of imaging technologies in eye care.

From laser vision correction to adjustable lens implants, the Center for Refractive Solutions at New York Eye and Ear Infirmary of Mount Sinai offers advanced options for every stage of life.

To conduct the study, the investigators obtained data on coffee consumption from genome‐wide association studies (GWAS) and the latest AMD‐related GWAS summary data from the Finngen consortium R11.

Funding will support continued product development, while the board is composed of “global leaders in posterior and anterior segment eye care, artificial intelligence and clinical trial design.”

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive retinal disease.

Assistive devices empower patients with central vision loss to regain independence, enhancing daily activities and reducing reliance on low vision centers.

Timely diagnosis and personalized treatment are key to improving visual outcomes.

With detailed imaging and cognitive data, the Northern Ireland Cohort for the Longitudinal Study of Aging highlights the potential of integrating eye scans into broader health research.

Optical coherence tomography markers—like the ellipsoid zone—are reshaping clinical trials in intermediate age-related macular degeneration, as highlighted at the 2025 International SPECTRALIS Symposium — And Beyond (ISS).

Ocular Therapeutix showcases innovative retinal disease treatments at the Clinical Trials Summit 2025 in Las Vegas, featuring presentations and discussions.

Advanced monitoring strategies are overcoming significant obstacles in retinal care, as highlighted at the 2025 International SPECTRALIS Symposium — And Beyond (ISS).

The trial treated 9 patients in 3 sequential, ascending dose-level (DL) cohorts.

Fluorescence lifetime imaging ophthalmoscopy is emerging as a valuable tool to reveal previously hidden links between retinal changes and systemic disease.